|
CD8+
T-cell response of patients with HOM-MEL-40/SSX2 positive breast
cancers to HOM-MEL-40/SSX2-derived p103-111.
|
Patient
|
Age
|
Stage
|
Therapy
at Time of Blood Sample
|
Anti-SSX2
Ab
Reactivity
|
p103-111
Reactivity
|
|
G218
|
65
|
T1c,
N1b3, M0, GIII
|
surgery
|
-
|
+
|
|
G221
|
61
|
T2,
N1b4, Mx, GIII
|
surgery
|
-
|
+
|
|
G231
|
52
|
T1c,
N0, M0, GIII
|
surgery
|
-
|
-
|
|
G237
|
69
|
T2,
N1b3, M0, GIII
|
surgery
|
-
|
-
|
|
G244
|
59
|
T2,
N1b1, M0, GII
|
surgery
|
-
|
+
|
|
G312
|
50
|
T3,
N1b2, M1, GIII
|
chemotherapy
|
-
|
+
|
|
G313
|
73
|
T2,
N0, M0, GII
|
surgerya
|
-
|
+
|
aSurgery
of second primary; previous therapy (8 years prior to second primary):
segment resection of primary tumor followed by adjuvant chemotherapy
plus radiotherapy followed by tamoxifen maintenance therapy.
|
